Relugolix
- Generic Name
- Relugolix
- Brand Names
- Myfembree, Orgovyx
- Drug Type
- Small Molecule
- Chemical Formula
- C29H27F2N7O5S
- CAS Number
- 737789-87-6
- Unique Ingredient Identifier
- P76B05O5V6
- Background
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment ...
- Indication
适用于治疗成年晚期前列腺癌症患者。
- Associated Conditions
- Advanced Hormone Sensitive Prostate Cancer, Advanced Prostate Cancer, Heavy Menstrual Bleeding, Severe Pain
- Associated Therapies
- -
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
- Conditions
- Interventions
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 2250
- Registration Number
- NCT05605964
- Locations
- 🇺🇸
Lowcountry Urology Clinics, North Charleston, South Carolina, United States
🇺🇸NorthShore University Health System - Glenbrook Hospital Ambulatory Care Center Satellite, Glenview, Illinois, United States
🇺🇸SG Research LLC, Miami, Florida, United States
A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 999
- Registration Number
- NCT05467176
- Locations
- 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸Ascend Pharma Holdings, Houston, Texas, United States
RElugolix VErsus LeUprolide Cardiac Trial
- Conditions
- Biochemically Recurrent Prostate CarcinomaLocalized Prostate CarcinomaStage I Prostate Cancer AJCC V8Stage II Prostate Cancer AJCC V8Stage IIA Prostate Cancer AJCC V8Stage IIB Prostate Cancer AJCC V8Stage IIC Prostate Cancer AJCC V8Stage III Prostate Cancer AJCC V8Stage IIIA Prostate Cancer AJCC V8Stage IIIB Prostate Cancer AJCC V8
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Emory University
- Target Recruit Count
- 93
- Registration Number
- NCT05320406
- Locations
- 🇺🇸
Emory Proton Therapy Center, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 260
- Registration Number
- NCT05053152
- Locations
- 🇺🇸
Trinity Health Saint Joseph Mercy Oakland Hospital, Pontiac, Michigan, United States
🇺🇸Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, United States
🇺🇸Munson Medical Center, Traverse City, Michigan, United States
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT04978688
- Locations
- 🇺🇸
Clinical Study Site, Minneapolis, Minnesota, United States
A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men
- Conditions
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 43
- Registration Number
- NCT04714554
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, An Evolution Research Group Portfolio Company, Hialeah, Florida, United States
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT04666129
- Locations
- 🇺🇸
Clinical Research Alliance, Inc., Westbury, New York, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Alliance Urology, Greensboro, North Carolina, United States
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 108
- Registration Number
- NCT04523207
- Locations
- 🇺🇸
Urological Research Network, Hialeah, Florida, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Conditions
- Interventions
- Procedure: Computed TomographyRadiation: 3-Dimensional Conformal Radiation TherapyDrug: ApalutamideDrug: DegarelixRadiation: External Beam Radiation TherapyOther: Fluciclovine F18Drug: Goserelin AcetateDrug: Leuprolide AcetateProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Intensity-Modulated Proton TherapyOther: Quality-of-Life AssessmentRadiation: Intensity-Modulated Radiation TherapyOther: Questionnaire AdministrationDrug: RelugolixDrug: TriptorelinRadiation: Stereotactic Body Radiation TherapyRadiation: Volume Modulated Arc Therapy
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 804
- Registration Number
- NCT04423211
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.